25B-NBOMe

25B-NBOMe (2C-B-NBOMe; Cimbi-36) is a synthetic N-benzylphenethylamine psychedelic compound and potent full agonist at the serotonin 5-hydroxytryptamine type 2A (5-HT2A) receptor, with reported binding affinities (Ki) of 0.19 to 0.8 nanomolar at the human 5-HT2A receptor, 0.5 nanomolar at the 5-HT2B receptor, and 1.7 to 6.2 nanomolar at the 5-HT2C receptor [1, 2]. The compound is the N-(2-methoxybenzyl) derivative of 4-bromo-2,5-dimethoxyphenethylamine (2C-B), first synthesized by Ralf Heim at the Free University of Berlin in 2003 as part of a systematic exploration of N-benzyl substitution on phenethylamine 5-HT2A receptor agonist scaffolds [3]. The N-benzyl modification confers a 35- to 100-fold increase in 5-HT2A binding affinity relative to the parent 2C-B compound, producing one of the highest-affinity small-molecule 5-HT2A agonists characterized to date, with greater than 200-fold selectivity over non-serotonergic monoamine receptors and greater than 1000-fold selectivity for 5-HT2A over 5-HT1A [1, 4].

The primary scientific application of 25B-NBOMe is as a pharmacological tool for investigating serotonin 5-HT2A receptor function. In its carbon-11 radiolabeled form, [11C]Cimbi-36, the compound is the first agonist positron emission tomography (PET) radioligand validated for human brain 5-HT2A receptor imaging, with demonstrated cortical distribution matching known 5-HT2A receptor density, successful blockade by the selective 5-HT2A antagonist ketanserin, and favorable dosimetry permitting repeated scanning in a single subject [5, 6]. Multiple PET research centers employ [11C]Cimbi-36 for receptor occupancy studies, investigations of endogenous serotonin release, and characterization of psychedelic drug pharmacology.

Preclinical pharmacology in rodent models demonstrates that 25B-NBOMe produces dose-dependent increases in extracellular dopamine, serotonin, and glutamate in the frontal cortex, striatum, and nucleus accumbens; induces the 5-HT2A-mediated head-twitch response at potency comparable to 25I-NBOMe; impairs recognition memory in the novel object recognition test at higher doses; and produces mild DNA damage in the comet assay at substantially lower magnitude than MDMA [7, 8]. The compound also produces conditioned place preference and self-administration in rodent models, with the reinforcing effects mediated through dopaminergic mechanisms in the nucleus accumbens, distinguishing 25B-NBOMe from classical serotonergic psychedelics that typically lack reinforcing properties [9].

Pharmacokinetics are dominated by extensive hepatic first-pass metabolism, rendering the compound inactive by the oral route and necessitating sublingual, buccal, or intranasal administration at microgram-level doses (200 to 700 micrograms). Cytochrome P450 2D6 (CYP2D6) accounts for approximately 69 percent of metabolic clearance, with additional contributions from CYP1A2, CYP2B6, CYP2C19, and CYP3A4 [1, 10]. Over 60 phase I and phase II metabolites have been identified, with O-demethylation, hydroxylation, and N-dealkylation as the principal biotransformation pathways [10, 11].

25B-NBOMe carries a significant toxicological burden. Clinical case series document over 50 acute toxicity presentations and at least two fatalities directly attributable to the compound, with the toxidrome characterized by severe agitation, hallucinations, tachycardia, hypertension, hyperthermia, seizures, rhabdomyolysis, metabolic acidosis, and multiorgan failure [12, 13, 14]. No specific antidote exists; management is symptomatic with benzodiazepines, antipsychotic agents, and supportive care. The compound is classified as a Schedule I controlled substance in the United States (permanently scheduled in 2016), a Class A drug in the United Kingdom, and is included in the United Nations Convention on Psychotropic Substances Schedule I [15]. This monograph documents the chemistry, synthesis, receptor pharmacology, pharmacokinetics, preclinical pharmacology, toxicology, and comparative assessment of 25B-NBOMe for research-use-only applications.